Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.640 +0.130 (+2.36%)
Official Closing Price Updated: 4:15 PM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Exposures Animal Testing Artificial Intelligence Product Safety
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 
Via Stocktwits
Topics Animal Testing
Exposures Animal Testing Product Safety
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
Why Recursion Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
The market is filled with gapping stocks in Friday's session.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Recursion Pharmaceuticals Shares Are Up Today: what's Going On?
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug... 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated
Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery. 
Via Stocktwits
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs." 
Via Benzinga
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Via The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits. 
Via The Motley Fool
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Via The Motley Fool
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham. 
Via Benzinga
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.